Autolus Therapeutics plc (NASDAQ: AUTL) is a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer and autoimmune diseases. Utilizing advanced T-cell programming technology, the company focuses on designing targeted therapies—such as its lead product candidate obe-cel (obecabtagene autoleucel)—to enhance cell persistence, improve tumor recognition, and address safety hurdles associated with conventional chimeric antigen receptor (CAR) T-cell therapies.